Lenvatinib - Eisai Co Ltd/Merck & Co
At a glance
- Drug Originator Eisai Co Ltd
- Drug Licenced by Biotoscana; Ewopharma; Merck & Co; Novartis Pharmaceuticals Corporation
- Drug Class Amides; Antineoplastics; Chlorobenzenes; Cyclopropanes; Eye disorder therapies; Phenyl ethers; Quinolines; Small molecules; Urea compounds
- Mechanism of Action Platelet-derived growth factor alpha receptor antagonists; Proto-oncogene protein c-kit inhibitors; Proto-oncogene protein c-ret inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type 4 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
- USA Patent Applicants EISAI INC
- USA Patents 13
- NDAs 1
- International Patents 185
- Patent Applications 204
Table of Contents
Disclaimer